Key result
Anti-PECAM-1 antibody reduces myocardial infarct size by ~54% in rat ischemia-reperfusion injury.
Why the study?
Antibodies to neutrophil or endothelial cell adhesion molecules reduce myocardial infarct size, but the effect of anti-PECAM-1 antibody in myocardial infarction was not examined.
Does anti-PECAM-1 antibody reduce myocardial infarct size in a rat model of ischemia-reperfusion injury?
Population
Male Wistar rats subjected to myocardial ischemia-reperfusion injury
Comparison
F(ab')2 fragments of anti-PECAM-1 antibody SEW16 vs normal rabbit IgG control
Design
Experimental study in a rat model of ischemia-reperfusion injury
Follow-up
2 hours reperfusion after 30-minute coronary occlusion
Authors
Loading...
Hypothesis-generating for PECAM-1 inhibition in ischemia-reperfusion injury; clinical translation requires prospective human trials.
Does anti-PECAM-1 antibody reduce myocardial infarct size in a rat model of ischemia-reperfusion injury?
Effect estimate: 54% decrease
Absolute Event Rate: 28.5% vs 62%
p-value: p=<.001
Blocking PECAM-1 significantly reduces myocardial infarct size and neutrophil accumulation in a rat model of ischemia-reperfusion injury.
Gumina et al. (1996) studied Myocardial ischemia-reperfusion injury (n=33). F(ab')2 fragments of anti-PECAM-1 antibody SEW16 vs. Untreated or control normal rabbit IgG (NRIgG) was evaluated on Myocardial infarct size (54% decrease, p=<.001). Administration of anti-PECAM-1 antibody SEW16 reduced myocardial infarct size by 54% compared to controls (28.5% vs 62%; P<.001) in a rat model of ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: